India, Dec. 3 -- Zydus Cadila has received the tentative approval from the US Food and Drug Administration (USFDA) to market Lorcaserin Hydrochloride Tablets (US RLD-Belviq Tablets), 10 mg. The drug is used together with diet and exercise to treat obesity. It will be manufactured at the group's formulations manufacturing facility at SEZ.

The group now has 278 approvals and has so far filed over 330 ANDAS since the commencement of the filing process in FY 2003-04.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, amon...